The Technical Analyst
SAB Biotherapeutics, Inc. [SABS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
SAB Biotherapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.13% $4.36
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 40.22 mill |
| EPS: | -7.64 |
| P/E: | -0.570 |
| Earnings Date: | May 14, 2024 |
| SharesOutstanding: | 9.23 mill |
| Avg Daily Volume: | 0.0145 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.570 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.570 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$6.91 (58.48%) $2.55 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.96 - 4.76 ( +/- 9.22%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-21 | Kropotova Alexandra | Buy | 140 000 | Employee Stock Option (right to buy) |
| 2024-02-21 | Sullivan Eddie Joe | Buy | 190 000 | Employee Stock Option (right to buy) |
| 2024-02-21 | Bausch Christoph Lawrence | Buy | 140 000 | Employee Stock Option (right to buy) |
| 2024-02-21 | King Michael | Buy | 115 000 | Employee Stock Option (right to buy) |
| 2024-02-21 | Reich Samuel J | Buy | 434 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 70.15 |
| Last 88 transactions |
| Buy: 19 783 333 | Sell: 3 137 658 |
Forecast:
13:30 - $4.37
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $4.36 (-1.13% ) |
| Volume | 0.0008 mill |
| Avg. Vol. | 0.0145 mill |
| % of Avg. Vol | 5.43 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SABS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Latest Press Releases
2024-04-16 07:15:00 - Press Release
Sab Biotherapeutics Provides Sab-142 Trial Update
Miami beach, fla., april 16, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs ), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced their chief medical officer, dr. alexandra kropotova, md, mba disclosed that sab has completed dosing the third cohort for sab-142 with no observation of serum sickness thus far.
2024-04-08 07:15:00 - Press Release
Sab Biotherapeutics To Present At Innodia Annual Meeting
Miami beach, fla., april 08, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs ), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced their chief medical officer, dr. alexandra kropotova, md, mba will share an overview of the sab-142 clinical development plan and anticipated milestones at the innodia annual meeting in leuven, belgium on april 11, 2024.
2024-04-04 07:15:00 - Press Release
Sab Biotherapeutics To Present At The Needham Virtual Healthcare Conference
Miami, fl , april 04, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs ), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced samuel j. reich, the company's chairman and ceo, will present an overview of the company at the upcoming 23rd annual needham virtual conference on thursday, april 11, 2024 at 1:30 p.m. et.
2024-03-29 07:15:00 - Press Release
Sab Biotherapeutics Reports Full Year 2023 Operating And Financial Results
Sioux falls, sd , march 29, 2024 (globe newswire) -- sab biotherapeutics reports full year 2023 operating and financial results march 29, 2024 sab-142 phase 1 trial on track for data release during 2024 completed financing for up to $110 million with leading life science investors cash and equivalents of $56.6 million as of december 31, 2023 company expects its cash and equivalents, with exercise of tranche b warrants, will fund operations into 2026 sioux falls, sd march 29, 2024 (globenewswire)—sab biotherapeutics, inc. (nasdaq:sabs), (“sab” or “the company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced its financial results for the fourth quarter of 2023 in addition to its full year financial results for the fiscal year ended december 31, 2023, and reported on recent accomplishments and expected upcoming milestones...
2024-03-25 10:15:00 - Press Release
Sab Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center To Advance Potential Influenza Treatment
Sioux falls, s.d., march 25, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced that the navy medical research command (nmrc) is moving forward with a safety and tolerability study to evaluate sab-176, a therapy being investigated for use as a pre- and post-exposure prophylactic treatment for influenza type a and type b, pursuant to the cooperative research and development agreement that governs the relationship between sab and the nmrc.
Latest News
2024-04-08 07:15:00 - GlobeNewsWire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.
2024-04-04 07:15:00 - GlobeNewsWire
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company's Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m. ET.
2024-02-23 08:00:00 - GlobeNewsWire
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 3:15 PM EST.
2024-02-08 08:00:00 - GlobeNewsWire
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST.
2023-12-08 11:16:50 - Zacks Investment Research
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2023-05-30 08:30:00 - GlobeNewsWire
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176 SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176
2023-05-03 17:00:00 - GlobeNewsWire
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
SIOUX FALLS, S.D., May 03, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin IgG1 (polyclonal) antibodies without the need for human donors, is pleased to announce that Eddie Sullivan, PhD, co-founder, President & CEO of SAB Biotherapeutics, will be presenting and hosting one-on-one meetings with investors at the upcoming Sidoti Virtual Investor Conference on May 10 at 11:30am ET. The presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/WN_hky73f7PSt6rJa3TODNaAQ.
2023-04-18 08:17:55 - MarketBeat
Promising Upsides on these Biotech Penny Stocks
For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet profitable, but they offer the potential for high growth as their products gain regulatory approval and market acceptance.
2023-04-13 12:44:52 - Proactive Investors
SAB Biotherapeutics up 80% after FDA grants fast-track status to flu therapeutic
SAB Biotherapeutics (NASDAQ:SABS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic SAB-176 for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains, causing the company's shares to shoot up more than 80%. A Fast Track designation allows drugmakers to expedite the development and review of medicines that target critical illnesses and address unmet medical needs.
2022-12-15 08:30:00 - GlobeNewsWire
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting, an investor conference that drives biotech innovation and global collaboration through presentations delivered by innovative biotech companies, face-to-face networking and one-to-one meetings. The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.